Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

liposomal Chk1 inhibitor SMP-3124 SMP-3124LP

A liposomal formulation containing an inhibitor of checkpoint kinase 1 (chk1), with potential antineoplastic and chemosensitization activities. Upon administration of liposomal chk1 inhibitor SMP-3124 SMP-3124LP, SMP-3124 selectively targets and binds to chk1, thereby preventing activity of chk1 and abrogating the repair of damaged DNA. This may lead to an accumulation of damaged DNA, inhibition of cell cycle arrest, and induction of apoptosis. Chk1, an ATP-dependent serine/threonine kinase, is activated by DNA damage response and mediates cell cycle checkpoint control. It is essential for DNA repair and plays a key role in resistance to chemotherapeutic agents.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:liposomal Chk1 inhibitor SMP-3124
liposomal SMP 3124
liposomal SMP-3124
liposomal SMP3124
Code name:SMP 3124LP
SMP-3124LP
SMP3124LP
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search